Application of tanshinone IIA sulfonatesodium in preparation of medicine

A technology of sodium sulfonate and tanshinone, which is applied in the directions of drug combination, pharmaceutical formula, medical preparation containing active ingredients, etc., can solve problems such as single species

Pending Publication Date: 2022-02-22
SPH NO 1 BIOCHEM & PHARMA CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The technical problem to be solved in the present invention is to overcome the single defect of existing LDH inhibitors, and provide the application of tanshinone IIA sulfonate sodium in the preparation of medicines

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of tanshinone IIA sulfonatesodium in preparation of medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] 1. Trial grouping and intervention

[0023] Sham operation group (SHAM group): 10 rats

[0024] Experimental group (ligation of the left anterior descending coronary artery), a total of 80 rats (see: Gao E, KochWJ. A novel and efficient model of coronary artery ligation in them. Methods in Molecular Biology (Clifton, N.J. ).2013;1037:299-311):

[0025] (1) STS 20.8mg / kg / d: 20 pieces

[0026] (2) Normal saline group: 20 rats

[0027] Administration method: intraperitoneal injection of the required dose of drugs or normal saline 1 hour before ligation of the left anterior descending coronary artery; then intraperitoneal injection of corresponding doses of drugs every day.

[0028] 2. Experimental results

[0029] Sodium tanshinone IIA sulfonate (STS) can reduce the level of LDH

[0030] Blood was collected from the right ventricle at 12 hours (12h) and 3 days (3d) after myocardial infarction, and the myocardial enzyme lactate dehydrogenase (LDH) was detected. Clinic...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of tanshinone IIA sulfonate sodium in preparation of a medicine. Blood is taken from the right ventricle 12 hours and 3 days after myocardial infarction, and the myocardial enzyme lactic dehydrogenase is detected. After the tanshinone IIA sulfonate sodium is used, LDH level begins to decrease after myocardial infarction for 12 hours, myocardial cell necrosis or injury begins to decrease, and significant difference is achieved in 3 days, so that the tanshinone IIA sulfonate sodium can significantly inhibit LDH level in plasma, especially LDH increase caused by myocardial cell necrosis or injury. Therefore, the tanshinone IIA sulfonate sodium can effectively inhibit the LDH level in a mouse body, and can be used for preparing antiepileptic drugs.

Description

technical field [0001] The invention relates to the application of sodium tanshinone IIA sulfonate in the preparation of medicines. Background technique [0002] Epilepsy refers to persistent or secondary changes in the brain with epileptic seizures as the main manifestation, and can cause serious consequences in neurobiology, psychology, sociology, and cognitive function. The etiology of epilepsy is complex and diverse, including genetic factors, brain diseases, systemic or systemic diseases, etc. In 2010, it was first discovered that acute myocardial infarction can cause epilepsy (Liu Xiqiang, Li Li. A case of acute myocardial infarction first diagnosed with epilepsy [J]. Journal of Clinical Cardiovascular Diseases, 2010, 026(007): 559-559.). According to statistics in 2016, there are about 50 million epilepsy patients in the world, especially with the aging of the population, this number is still expanding. Epilepsy is usually controllable but difficult to cure. Even wi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/58A61P25/08A61P9/10
CPCA61K31/58A61P25/08A61P9/10
Inventor 姜红张宝丽于鹏刘明苏恩勇黄臻辉
Owner SPH NO 1 BIOCHEM & PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap